Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients Undergoing Coronary Angiography and/or Intervention

Phase 2/3 Completed 208 enrolled Onassis Cardiac Surgery Centre

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The prevention of contrast-mediated nephropathy (CMN), which accounts for considerable morbidity and mortality, remains a vexing problem. Contrast induced renal vasoconstriction is believed to play a pivotal role in the CMN mechanism. The aim of this study is to examine the efficacy of the prostacyclin analogue iloprost (dose 1ng/kg/min) in preventing CMN in high-risk patients undergoing a coronary procedure.

Timeline

Start: 2005-11
Primary completion: —
Completion: 2007-07

Outcome

Met primary endpoint

paper Contrast-induced nephropathy occurred in 23 of the 105 patients (22%) in the control group and in 8 of the 103 patients (8%) PMID 19841299 ↗

paper odds ratio, 0.29; 95% confidence interval, 0.12 to 0.69; P=0.005 PMID 19841299 ↗

Publications

Spargias K, Adreanides E, Demerouti E, Gkouziouta A, Manginas A, Pavlides G, Voudris V, Cokkinos DV. Iloprost prevents contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2009 Nov 3;120(18):1793-9. doi: 10.1161/CIRCULATIONAHA.109.863159. Epub 2009 Oct 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Iloprost	Other / unclassified	1 ng/ml	Intravenous